Oral Semaglutide Cuts Heavy Drinking; VA Launches Alcoholism Trial
Oral semaglutide cut heavy drinking and cravings in an 8-week AUD trial. The VA is testing semaglutide in the CRAVE trial enrolling more than 600 veterans.
Alcohol Use Disorder
DiseaseAlso known as: alcohol addiction, AUD
Disease Profile
Alcohol use disorder is a medical condition characterized by an impaired ability to stop or control alcohol use despite adverse social, occupational, or health consequences. It can range from mild to severe and may involve tolerance and withdrawal.
- Category
- substance use disorder
- Prevalence
- Common
- F10.20
Related News
FDA Finalizes Psychedelic Clinical Trial Guidance; States Move on Ibogaine Research
FDA final guidance sets standards for psychedelic clinical trials. Federal agencies and states are advancing psilocybin and ibogaine research, and Eli Lilly is acquiring AtaiBeckley for $2.8 billion.
Semaglutide Linked to Lower Seizure and Alcohol-Related Hospitalization Risks; Brazil Approves Five New GLP-1 Drugs
Semaglutide may lower risks of adult-onset seizures and alcohol-related hospitalizations, new studies find. Brazil approved five semaglutide injectables, and a commentary updates obesity care with GLP-1 drugs.
Adial completes AD04 demonstration batch production for planned Phase 3 trial
Adial Pharmaceuticals completed demonstration batch production for AD04, meeting prespecified specifications and matching the prior Phase 2 dissolution profile. The step enables clinical and registration batch production for the planned Phase 3 trial.
GLP-1 Drugs Discovered in Fish Research Now Treat Multiple Conditions
GLP-1 drugs discovered accidentally in anglerfish research now treat conditions beyond diabetes including kidney disease, sleep apnea, and addiction. The global diabetes therapeutics market is projected to reach $241.5 billion by 2030, growing at 12.4% annually.
Psilocybin studies link treatment to lasting shifts in values and fear of death
Studies of psilocybin found lasting shifts in life values in healthy volunteers and reduced fear of death in therapeutic settings. Trials have also reported benefits in cancer patients.
GLP-1 Drugs Show Promise in Treating Addiction Across Multiple Substances
A study of over 600,000 patients reveals GLP-1 drugs may reduce addiction across multiple substances, with 50% fewer substance-related deaths and significant reductions in overdoses and hospitalizations. The drugs work by dampening dopamine signaling in brain reward centers. Researchers are exploring broader applications for these medications beyond diabetes and obesity treatment.
Ketamine's Therapeutic Benefits Not Linked to Psychedelic Effects in Alcohol Use Disorder
New research challenges the theory that ketamine's psychedelic effects drive its therapeutic benefits for alcohol use disorder. A study of 96 participants found no link between ketamine's psychoactive experiences and improved abstinence rates. The findings suggest other mechanisms, such as brain network alterations, may explain ketamine's effectiveness in treating addiction.
Altimmune Advances Pemvidutide with FDA Breakthrough Designation and Phase 3 MASH Trial Planned
Altimmune's pemvidutide received FDA Breakthrough Therapy Designation for MASH treatment, with Phase 3 trial initiation planned for 2026. The company raised $75 million in January 2026 to fund development.
GLP-1 Drugs Show Protective Effects Against Addictions, Parkinson's, and Endometrial Cancer
New research reveals GLP-1 receptor agonists reduce substance use disorders by 14%, lower Parkinson's disease risk after 5-10 years of use, and cut endometrial cancer risk by 66% when combined with progestin therapy.
Related Clinical Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07748078 |
Snoezelen Therapy in Adults With Alcohol Dependence and Adults With Schizophrenia |
NOT_YET_RECRUITING | NA |
| NCT07728968 |
The 15-Mental Project: Implementation and Evaluation of the 15-Mental in a Mental Health Hospital Setting |
ACTIVE_NOT_RECRUITING | NA |
| NCT07724275 |
Understanding Pathways to Wellness and Recovery in Detroit - Digital Recovery Support Services |
RECRUITING | NA |
| NCT07713251 |
Supporting Adolescent Alcohol Treatment With Computer-Based ('Path180') Skills Training |
RECRUITING | NA |
| NCT07701928 |
Daridorexant for People With Insomnia and Alcohol Use Disorder Study |
NOT_YET_RECRUITING | PHASE2 |
| NCT07692984 |
The Effect of Comorbid Alcohol/Substance Use |
RECRUITING | |
| NCT07681869 |
Effects of Nimodipine on Alcohol Drinking |
NOT_YET_RECRUITING | PHASE2 |
| NCT07678567 |
Pomegranate Dietary Supplements in AUD and ALD |
NOT_YET_RECRUITING | |
| NCT07677449 |
Preventing Harmful Alcohol Use Among Trauma Patients in Cameroon |
NOT_YET_RECRUITING | NA |
| NCT07667790 |
Effects of Olfactory Stimuli in Virtual Reality Cue Exposure on Craving and Attentional Bias in Alcohol Use Disorder |
NOT_YET_RECRUITING | NA |